Prohost Letters
Premium
Prohost Letter #388
Prohost Letter #388 TOPICS - 1. AN INDISPENSABLE SHORT INTRODUCTION 2. GENE EDITING 3. GENE THERAPY 4. CANCER IMMUNOTHERAPY 1. GENE EDITING Exon Skipping: Biomarin (BMRN); Sarepta (SRPT); These firms...
P
Prohost Biotech
1 min read
11
0
Unlock Premium Content
This article contains exclusive content for our premium subscribers. Join our community to access in-depth research, expert insights, and comprehensive analysis.
Unlimited articles
Expert analysis
Research reports
Tags
AdaptImmune Therapeutics (ADAP)
Agenus (AGEN)
Akashi Therapeutics
Alnylam Pharmaceuticals (ALNY)
Amgen (AMGN)
Arbutus Biopharma (ABUS)
Bellicum Pharmaceuticals Inc (BLCM)
BioMarin Pharmaceutical (BMRN)
Bristol-Myers Squibb (BMY)
CAR-T
Catabasis Pharmaceuticals Inc (CATB)
Cellectis (CLLS)
Compugen (CGEN)
CRISPR Therapeutics (CRSP)
Incyte (INCY)
Ionis Pharmaceuticals Inc (IONS)
Juno Therapeutics (JUNO)
Kite Pharma - A Gilead Company
Merck (MRK)
Prohost Portfolio
PTC Therapeutics (PTCT)
Sangamo Therapeutics Inc (SGMO)
Sarepta Therapeutics (SRPT)
Spark Therapeutics
Summit Therapeutics (SMMT)
Ziopharm Oncology (ZIOP)
Comments (0)
Please sign in to join the discussion